Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/22881
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wong, Anselm Y | - |
dc.contributor.author | Isbister, Geoff | - |
dc.contributor.author | McNulty, Richard | - |
dc.contributor.author | Isoardi, Katherine | - |
dc.contributor.author | Harris, Keith | - |
dc.contributor.author | Chiew, Angela | - |
dc.contributor.author | Greene, Shaun | - |
dc.contributor.author | Gunja, Naren | - |
dc.contributor.author | Buckley, Nicholas | - |
dc.contributor.author | Page, Colin | - |
dc.contributor.author | Graudins, Andis | - |
dc.date | 2020-03-19 | - |
dc.date.accessioned | 2020-03-31T03:15:24Z | - |
dc.date.available | 2020-03-31T03:15:24Z | - |
dc.date.issued | 2020-03 | - |
dc.identifier.citation | EClinicalMedicine 2020; 20: 100288 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/22881 | - |
dc.description.abstract | Previous studies of paracetamol overdose treatment show that a 2-bag, 20-h intravenous (IV) acetylcysteine regimen decreased the incidence of non-allergic anaphylactic reactions compared to the 3-bag, 21 h IV regimen, but have not examined efficacy of the 20-h 2 bag regimen. This was a multi-centre observational study of paracetamol overdose presentations treated with a 2-bag IV acetylcysteine regimen (200 mg/kg over 4 h, 100 mg/kg over 16 h) compared to a 3-bag regimen, performed from 2009 to 2019. Patients were referred from the emergency department to the inpatient toxicology units for continued management. For the primary non-inferiority analysis: subjects had single, acute ingestions, a serum paracetamol-concentration performed 4 to 8-h post-ingestion. The primary outcome was development of acute liver injury (ALI), defined as peak ALT>150 U/L; and > double admission baseline ALT (for presentations within 24 h post-overdose). Secondary outcomes included adverse reactions to acetylcysteine (cutaneous and systemic). Out of 6419 paracetamol overdoses, 2763 received acetylcysteine. For the primary analysis, 1003 received the 2-bag and 783 the 3-bag acetylcysteine regimen. When presentation bloods were performed 4 to 8-h post-overdose, 21 (3.1%) developed ALI with the 2-bag regimen vs 16 (2.9%) with the 3-bag regimen (Difference: 0.2%, 95%CI:-1.6 to 2.2). The incidence of hepatotoxicity was: 1.2% (n = 8) with the two-bag regimen and 1.6% (n = 9) with the three-bag regimen (Difference -0.4%, 95%CI -1.75, 0.91). When presentation bloods were performed 8 to 24-h post-overdose, 70 (21%) developed ALI with the 2-bag regimen vs 46 (23%) with the 3-bag regimen (Difference: -2%, 95%CI -9.12 to 5.36). There were significantly less cutaneous and systemic non-allergic anaphylactic reactions recorded after treatment with the two-bag than the three-bag regimen (1.3% [n = 17] and 7.1% [n = 65], Difference: -5.8%, 95%CI -7.6 to -4.0, p < 0.0001), respectively. A two-bag intravenous acetylcysteine regimen was found to be non-inferior to the three-bag regimen with regards to efficacy in preventing acute liver injury for early presentations of paracetamol overdose. No important differences were seen for any other presentations. The two-bag regimen also decreased the incidence of both non-allergic anaphylactic reactions and gastrointestinal adverse events from acetylcysteine treatment. AW is funded by a National Health and Medical Research Council (NHMRC) Early Career Fellowship ID 1159907. GI is funded by a NHMRC Senior Research Fellowship ID 1061041. The NHMRC had no role in the design, writing of this manuscript. The corresponding author (AW) had full access to all the data in the study and final responsibility for the decision to submit the manuscript for publication. | - |
dc.language.iso | eng | - |
dc.subject | Acetaminophen | - |
dc.subject | N-acetylcysteine | - |
dc.subject | Poisoning | - |
dc.title | Efficacy of a two bag acetylcysteine regimen to treat paracetamol overdose (2NAC study). | - |
dc.type | Journal Article | - |
dc.identifier.journaltitle | EClinicalMedicine | - |
dc.identifier.affiliation | Monash Toxicology Unit, Dandenong Hospital, Monash Health, Victoria, Australia | en |
dc.identifier.affiliation | Victorian Poisons Information Centre, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | NSW Poisons Information Centre, Children's Hospital at Westmead, Westmead, NSW, Australia | en |
dc.identifier.affiliation | Austin Toxicology Service, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | School of Medicine, The University of Queensland, Brisbane, Queensland, Australia | en |
dc.identifier.affiliation | Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Victoria, Australia | en |
dc.identifier.affiliation | Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, Queensland, Australia | en |
dc.identifier.affiliation | Department of Pharmacology, Faculty of Medicine and Health, University of Sydney, Australia | en |
dc.identifier.affiliation | Western Sydney Toxicology Service, Western Sydney LHD, Sydney, Australia | en |
dc.identifier.affiliation | Department of Emergency Medicine, Westmead Hospital, Sydney, Australia | en |
dc.identifier.affiliation | Centre for Integrated Critical Care, Department of Medicine and Radiology, University of Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Department of Forensic Medicine, Monash University, Victoria, Australia | en |
dc.identifier.affiliation | Guy's and St Thomas' NHS Foundation Trust, United Kingdom.. | en |
dc.identifier.affiliation | Clinical Toxicology Unit, Princes of Wales Hospital, Randwick, NSW, Australia | en |
dc.identifier.affiliation | Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, Australia | en |
dc.identifier.affiliation | Department of Emergency Medicine, Blacktown Mount Druitt hospitals, Sydney, Australia | en |
dc.identifier.affiliation | Clinical Toxicology Research Group, University of Newcastle, NSW, Australia | en |
dc.identifier.affiliation | Department of Clinical Toxicology, Calvary Mater Newcastle, NSW, Australia | en |
dc.identifier.affiliation | Faculty of Medicine, University of Queensland, Brisbane, Australia | en |
dc.identifier.affiliation | Pharmacology, Faculty of Medicine and Health, University of Sydney, Australia | en |
dc.identifier.affiliation | Emergency Medicine, Westmead Clinical School, University of Sydney, Australia | en |
dc.identifier.doi | 10.1016/j.eclinm.2020.100288 | - |
dc.identifier.orcid | 0000-0002-6817-7289 | - |
dc.identifier.pubmedid | 32211597 | - |
dc.type.austin | Journal Article | - |
local.name.researcher | Graudins, Andis | |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Toxicology | - |
crisitem.author.dept | Emergency | - |
crisitem.author.dept | Victorian Poisons Information Centre | - |
crisitem.author.dept | Victorian Poisons Information Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.